Van beleggers
voor beleggers
desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?

Ontvang nu dagelijks onze kooptips!

word abonnee

Wat na ABLYNX welke aandeln kunnen veel groeien om welke redenen.

3 Posts
| Omlaag ↓
  1. [verwijderd] 1 februari 2018 11:34
    Merus, bispecifieke antibodies zijn de toekomst. bivoorbeeld: Basel, June 28, 2016 - Today Novartis announced that it has entered into a collaboration and licensing agreement with Xencor for the development of bispecific antibodies for treating cancer. The agreement is the latest in a series of acquisitions and strategic collaborations between Novartis and biotech companies that have helped bolster its deep and diverse immuno-oncology pipeline.

    Traditional monoclonal antibodies target and bind to a single antigen. Bispecific antibodies are engineered to recognize and target two different antigens, which makes them potentially more effective in targeting complex diseases. A T-cell engaging bispecific antibody is able to bind an antigen on a tumor cell with one arm and engage T-cells capable of their destruction with the other.
3 Posts
|Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 913,25 -0,03%
EUR/USD 1,0874 +0,04%
FTSE 100 8.420,26 -0,22%
Germany40^ 18.716,50 -0,12%
Gold spot 2.415,21 0,00%
NY-Nasdaq Composite 16.685,97 -0,07%

Stijgers

NX FIL...
+8,76%
VIVORY...
+6,12%
Sif Ho...
+4,09%
RENEWI
+3,21%
HEIJMA...
+3,08%

Dalers

Corbion
-3,97%
ADYEN NV
-3,20%
EBUSCO...
-3,00%
SIGNIF...
-2,50%
PROSUS
-2,29%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links